Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 28 points (0.2%) at 16,953 as of Monday, June 9, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,914 issues advancing vs. 1,041 declining with 157 unchanged. The Drugs industry currently sits up 3.1% versus the S&P 500, which is up 0.2%. Top gainers within the industry include Idenix Pharmaceuticals ( IDIX), up 232.4%, Alnylam Pharmaceuticals ( ALNY), up 8.2%, Pharmacyclics ( PCYC), up 5.7%, Vertex Pharmaceuticals ( VRTX), up 2.4% and Illumina ( ILMN), up 2.0%. A company within the industry that fell today was Novo Nordisk A/S ( NVO), up 0.5%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Regeneron Pharmaceuticals ( REGN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Regeneron Pharmaceuticals is up $8.38 (2.7%) to $319.59 on average volume. Thus far, 357,237 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 945,800 shares. The stock has ranged in price between $311.61-$320.00 after having opened the day at $312.30 as compared to the previous trading day's close of $311.21. Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $30.5 billion and is part of the health care sector. Shares are up 13.1% year-to-date as of the close of trading on Friday. Currently there are 6 analysts who rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 7 rate it a hold. TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, poor profit margins and weak operating cash flow. Get the full Regeneron Pharmaceuticals Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.